Mofezolac
Title: Mofezolac
CAS Registry Number: 78967-07-4
CAS Name: 3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid
Additional Names: 3,4-di(p-methoxyphenyl)-5-isoxazoleacetic acid
Manufacturers' Codes: N-22
Molecular Formula: C19H17NO5
Molecular Weight: 339.34
Percent Composition: C 67.25%, H 5.05%, N 4.13%, O 23.57%
Literature References: Prostaglandin biosynthetase inhibitor. Prepn: R. G. Micetich et al., EP 26928; eidem, US 4327222 (1981, 1982 both to CDC Life Sci.). Physico-chemical properties: T. Ushio et al., Iyakuhin Kenkyu 22, 892 (1991). HPLC determn in plasma and urine: T. Marunaka, M. Maniwa, J. Chromatogr. 422, 227 (1987). Pharmacology: K. Tanaka et al., Yakuri to Chiryo 18, 3347 (1990), C.A. 114, 135911 (1991). Acute toxicity: K. Satoh et al., J. Toxicol. Sci. 15, Suppl 2, 1 (1990).
Properties: White crystalline powder; slight characteristic odor. mp 147.5°. pKa¢ ~3.3. uv max (methanol): 236 nm (e = 1.83 ´ 104). Soly at 20° (w/v%): DMF 68.7; chloroform 19.5; ethyl acetate 16.5; acetone 7.32; methanol 3.93; anhydr ethanol 3.72; ether 2.90; hexane 2.90 ´ 10-5; water 4.85 ´ 10-3. Partition coefficient (chloroform/water): 16.6 (pH 6); 1.87 (pH 7); 0.178 (pH 8). LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh).
Melting point: mp 147.5°
pKa: pKa¢ ~3.3
Log P: Partition coefficient (chloroform/water): 16.6 (pH 6); 1.87 (pH 7); 0.178 (pH 8)
Absorption maximum: uv max (methanol): 236 nm (e = 1.83 ´ 104)
Toxicity data: LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh)
Therap-Cat: Anti-inflammatory; analgesic.
Keywords: Analgesic (Non-Narcotic); Anti-inflammatory (Nonsteroidal); Arylacetic Acid Derivatives.

Others monographs:
FosmidomycinKallidinNimorazoleFlunarizine
Manganese SulfateStrontium LactateChlordantoinOxiniacic Acid
PirenzepineDichloro(2-chlorovinyl)arsine2-Naphthoic AcidCymarin
tert-ButylbenzeneStrontium IodideLomerizineFusidic Acid
©2016 DrugLead US FDA&EMEA